High-risk prostate cancer is defined by the 2015 NCCN guidelines as biopsy Gleason Score (bGS) of 8 to 10, or prostate-specific antigen (PSA) concentration of >20 ng/ml, or clinical stage T3a [2]. This evidence concerns the gene KLK3 and prostate cancer.